Thomas Bell - Regencell Bioscience Lead Independent Director

RGC Stock  USD 4.50  1.03  29.68%   

Director

Mr. Thomas D. Bell, Jr. is Lead Independent Director of the Company. He is the Chairman of our Nominating and Corporationrationrate Governance Committee. Mr. Bell is currently the Chairman of Mesa Capital Partners, a real estate investment company, and serves as a director at AGL Resources, Inc. and Norfolk Southern Corporation . Previously, he served as the nonexecutive Chairman of SecurAmerica LLC, a national commercial security company, from January 2010 until September 2012, and as the Chief Executive Officer and a director of Cousins Properties Incorporated, a real estate investment trust, from January 2001 until July 2009. Prior thereto, Mr. Bell served as senior advisor at Credit Suisse First Boston Corporationrationration, overseeing real estate activities. Mr. Bell also spent ten years with Young Rubicam and retired as the Chairman and Chief Executive Officer. Mr. Bell served as a director of Lincoln National Corporation Co. from May 1988 to May 2005. since 2011.
Age 66
Tenure 13 years
Address Chinachem Leighton Plaza, Causeway Bay, Hong Kong
Phone852 2155 0823
Webhttps://www.regencellbioscience.com

Regencell Bioscience Management Efficiency

The company has Return on Asset of (0.2559) % which means that on every $100 spent on assets, it lost $0.2559. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.4171) %, meaning that it generated no profit with money invested by stockholders. Regencell Bioscience's management efficiency ratios could be used to measure how well Regencell Bioscience manages its routine affairs as well as how well it operates its assets and liabilities. At present, Regencell Bioscience's Return On Assets are projected to slightly decrease based on the last few years of reporting. At present, Regencell Bioscience's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Return On Assets is expected to grow to 0.04, whereas Total Assets are forecasted to decline to about 10.8 M.
The company has 463.67 K in debt with debt to equity (D/E) ratio of 0.07, which may show that the company is not taking advantage of profits from borrowing. Regencell Bioscience has a current ratio of 13.66, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Debt can assist Regencell Bioscience until it has trouble settling it off, either with new capital or with free cash flow. So, Regencell Bioscience's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Regencell Bioscience sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Regencell to invest in growth at high rates of return. When we think about Regencell Bioscience's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Leora LevinDelek Drilling
54
Tal LeviDelek Drilling
44
Elane StockYum Brands
55
Tiffany ThomPatterson UTI Energy
43
Kathrine FredriksenSeadrill Limited
32
Samuel MerksamerTransocean
40
Harald ThorsteinSeadrill Limited
37
Michael CawleyNoble Plc
68
Yaacov FriedgootDelek Drilling
69
Tiffany CepakPatterson UTI Energy
45
Eytan RozenmanDelek Drilling
71
Terry HuntPatterson UTI Energy
69
Gabriel LastDelek Drilling
70
Asaf BartfeldDelek Drilling
66
Birgitte VartdalSeadrill Limited
40
Jon MarshallNoble Plc
68
Bert BekkerSeadrill Limited
76
Janet HillThe Wendys Co
68
KjellErik OstdahlSeadrill Limited
52
Frederico CuradoTransocean
59
Theodore XenohristosCAVA Group
44
Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine bioscience company. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong. Regencell Bioscience operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 13 people. Regencell Bioscience Holdings (RGC) is traded on NASDAQ Exchange in USA. It is located in Chinachem Leighton Plaza, Causeway Bay, Hong Kong and employs 12 people. Regencell Bioscience is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Regencell Bioscience Leadership Team

Elected by the shareholders, the Regencell Bioscience's board of directors comprises two types of representatives: Regencell Bioscience inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Regencell. The board's role is to monitor Regencell Bioscience's management team and ensure that shareholders' interests are well served. Regencell Bioscience's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Regencell Bioscience's outside directors are responsible for providing unbiased perspectives on the board's policies.
Jacques Vaillancourt, Executive Chairman of the Board
YiChung Chao, Special Director
YatPui Au, Chief Officer
Antonia Assang, Senior Management
Jeffrey Pontius, Independent Director
John Gray, President Director
Jack Tyrrell, Independent Director
Thomas Bell, Lead Independent Director
Wai Chung, COO Officer
Michelle Chan, Financial Controller
Charles Brymer, Independent Director
Mark Brown, CFO
Kenneth Booth, Director
Sean Keenan, Director
David Ownby, CFO, Principal Accounting Officer, Executive VP and Treasurer
Tien Chau, Executive Officer
Lee Thomas, Independent Director
Michael Campbell, Non-Executive Chairman of the Board
Robert McLeod, Director
Peter Ball, Director
Stephen Kaplan, Independent Director
Peter Brandow, Executive Vice President General Counsel
Douglas Fulcher, Independent Director
Gregory Dunn, Pres and COO
YatGai Au, Chairman Founder
Amy Miles, Chairperson and CEO
David Keyte, Independent Director
Susan Mitchell, Director
Alex Yemenidjian, Independent Director
Tim Mikula, Investor Relations
Peter Bala, President CEO, Director
George Ireland, Director
Michael McInnis, Independent Director

Regencell Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Regencell Bioscience a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Regencell Bioscience in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Regencell Bioscience's short interest history, or implied volatility extrapolated from Regencell Bioscience options trading.

Currently Active Assets on Macroaxis

When determining whether Regencell Bioscience offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Regencell Bioscience's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Regencell Bioscience Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Regencell Bioscience Holdings Stock:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regencell Bioscience Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.
Note that the Regencell Bioscience information on this page should be used as a complementary analysis to other Regencell Bioscience's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Complementary Tools for Regencell Stock analysis

When running Regencell Bioscience's price analysis, check to measure Regencell Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regencell Bioscience is operating at the current time. Most of Regencell Bioscience's value examination focuses on studying past and present price action to predict the probability of Regencell Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regencell Bioscience's price. Additionally, you may evaluate how the addition of Regencell Bioscience to your portfolios can decrease your overall portfolio volatility.
AI Investment Finder
Use AI to screen and filter profitable investment opportunities
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Is Regencell Bioscience's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regencell Bioscience. If investors know Regencell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regencell Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.45)
Return On Assets
(0.26)
Return On Equity
(0.42)
The market value of Regencell Bioscience is measured differently than its book value, which is the value of Regencell that is recorded on the company's balance sheet. Investors also form their own opinion of Regencell Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Regencell Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regencell Bioscience's market value can be influenced by many factors that don't directly affect Regencell Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regencell Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Regencell Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regencell Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.